These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17958982)

  • 1. Tolerability of anti-tuberculosis treatment and HIV serostatus.
    Lanternier F; Dalban C; Perez L; Bricaire F; Costagliola D; Caumes E
    Int J Tuberc Lung Dis; 2007 Nov; 11(11):1203-9. PubMed ID: 17958982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koulla-Shiro S
    East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi.
    Mwaungulu FB; Floyd S; Crampin AC; Kasimba S; Malema S; Kanyongoloka H; Harries AD; Glynn JR; Fine PE
    Bull World Health Organ; 2004 May; 82(5):354-63. PubMed ID: 15298226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status.
    Moreno S; Jarrin I; Iribarren JA; Perez-Elías MJ; Viciana P; Parra-Ruiz J; Gomez-Sirvent JL; Lopez-Aldeguer J; Gutierrez F; Blanco JR; Vidal F; Leal M; Rodríguez Arenas MA; Del Amo J;
    Int J Tuberc Lung Dis; 2008 Dec; 12(12):1393-400. PubMed ID: 19017448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tuberculosis in HIV-positive and HIV-negative drug users in Amsterdam].
    Keizer ST; Langendam MW; van Deutekom H; Coutinho RA; van Ameijden FJ
    Ned Tijdschr Geneeskd; 1998 Jan; 142(4):184-9. PubMed ID: 9557024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors.
    Javadi MR; Shalviri G; Gholami K; Salamzadeh J; Maghooli G; Mirsaeedi SM
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1104-10. PubMed ID: 17823987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.
    Burman W; Weis S; Vernon A; Khan A; Benator D; Jones B; Silva C; King B; LaHart C; Mangura B; Weiner M; El-Sadr W
    Int J Tuberc Lung Dis; 2007 Dec; 11(12):1282-9. PubMed ID: 18229435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners.
    Sonnenberg P; Glynn JR; Fielding K; Murray J; Godfrey-Faussett P; Shearer S
    J Infect Dis; 2005 Jan; 191(2):150-8. PubMed ID: 15609223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
    Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment.
    Bliven-Sizemore EE; Johnson JL; Goldberg S; Burman WJ; Villarino ME; Chaisson RE;
    Int J Tuberc Lung Dis; 2012 Apr; 16(4):473-9. PubMed ID: 22325844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with tuberculosis treatment default among HIV-infected tuberculosis patients in Thailand.
    Kittikraisak W; Burapat C; Kaewsa-ard S; Watthanaamornkiet W; Sirinak C; Sattayawuthipong W; Jittimanee S; Pobkeeree V; Varma JK
    Trans R Soc Trop Med Hyg; 2009 Jan; 103(1):59-66. PubMed ID: 18937958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions.
    Lehloenya RJ; Todd G; Badri M; Dheda K
    Int J Tuberc Lung Dis; 2011 Dec; 15(12):1649-57. PubMed ID: 22118173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HIV seroprevalence in patients with tuberculosis].
    Nagai H; Kawabe Y; Nagayama N; Tanaka Y; Nishiyama M; Suzuki M; Masuda K; Baba M; Hori A; Tamura A; Akagawa S; Machida K; Kurashima A; Yotsumoto H; Mori M; Kimura S
    Kekkaku; 2001 Nov; 76(11):679-84. PubMed ID: 11766358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of treatment completion and fatality among tuberculosis patients in Spain.
    Caylà JA; Caminero JA; Rey R; Lara N; Vallés X; Galdós-Tangüis H;
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):458-64. PubMed ID: 15141739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.
    Pineda JA; Aguilar-Guisado M; Rivero A; Girón-González JA; Ruiz-Morales J; Merino D; Ríos-Villegas MJ; Macías J; López-Cortés LF; Camacho A; Merchante N; Del Valle J;
    Clin Infect Dis; 2009 Oct; 49(8):1274-82. PubMed ID: 19772387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review.
    Korenromp EL; Scano F; Williams BG; Dye C; Nunn P
    Clin Infect Dis; 2003 Jul; 37(1):101-12. PubMed ID: 12830415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
    Arbeláez MP; Arbeláez A; Gómez RD; Rojas C; Vélez L; Arias SL; Nagles J; Peláez LM; Betancourt G; Velásquez G
    Biomedica; 2007 Dec; 27(4):515-25. PubMed ID: 18320119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.
    d'Arminio Monforte A; Cozzi-Lepri A; Castagna A; Antinori A; De Luca A; Mussini C; Caputo SL; Arlotti M; Magnani G; Pellizzer G; Maggiolo F; Puoti M;
    Clin Infect Dis; 2009 Aug; 49(4):612-22. PubMed ID: 19591597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.